Horan Capital Advisors LLC. Has $5.34 Million Holdings in Merck & Co., Inc. (NYSE:MRK)

Horan Capital Advisors LLC. raised its stake in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 1.0% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 40,454 shares of the company’s stock after purchasing an additional 382 shares during the period. Merck & Co., Inc. makes up approximately 1.9% of Horan Capital Advisors LLC.’s portfolio, making the stock its 14th biggest holding. Horan Capital Advisors LLC.’s holdings in Merck & Co., Inc. were worth $5,338,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $27,000. Bare Financial Services Inc bought a new stake in shares of Merck & Co., Inc. during the 4th quarter worth $28,000. Burkett Financial Services LLC purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $28,000. Rakuten Securities Inc. bought a new position in Merck & Co., Inc. during the fourth quarter valued at about $30,000. Finally, RIA Advisory Group LLC bought a new stake in Merck & Co., Inc. in the fourth quarter worth about $30,000. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $126.45 on Friday. The stock has a market cap of $320.27 billion, a P/E ratio of 140.50, a PEG ratio of 2.44 and a beta of 0.38. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77. The business’s 50-day moving average price is $129.14 and its two-hundred day moving average price is $124.99. Merck & Co., Inc. has a twelve month low of $99.14 and a twelve month high of $134.63.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.21 billion. During the same period in the previous year, the business posted $1.40 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 8.9% on a year-over-year basis. As a group, equities analysts predict that Merck & Co., Inc. will post 8.62 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, July 8th. Shareholders of record on Monday, June 17th will be given a dividend of $0.77 per share. The ex-dividend date is Monday, June 17th. This represents a $3.08 dividend on an annualized basis and a yield of 2.44%. Merck & Co., Inc.’s payout ratio is 342.22%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Societe Generale cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price target on the stock. in a report on Monday, March 11th. Truist Financial upped their price target on Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Argus upgraded Merck & Co., Inc. to a “strong-buy” rating in a research note on Wednesday, June 5th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 target price on shares of Merck & Co., Inc. in a research note on Tuesday, June 18th. Finally, Berenberg Bank upped their price target on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a research note on Monday, April 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and a consensus target price of $133.00.

Read Our Latest Report on MRK

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.